Predictions
Viking Therapeutics Inc
Start price
Target price
Perf. (%)
€3.61
22.12.17
22.12.17
€9.92
18.09.18
18.09.18
458.13%
18.09.18
18.09.18
Ligand Pharmaceuticals
Start price
Target price
Perf. (%)
€172.55
15.06.18
15.06.18
€189.42
06.07.18
06.07.18
13.25%
06.07.18
06.07.18
Madrigal Pharmaceuticals inc.
Start price
Target price
Perf. (%)
€124.73
26.02.18
26.02.18
€135.30
31.05.18
31.05.18
56.77%
31.05.18
31.05.18
Karyopharm Therapeutics Inc.
Start price
Target price
Perf. (%)
€10.96
28.01.18
28.01.18
€12.45
08.02.18
08.02.18
13.66%
08.02.18
08.02.18
Five Prime Therapeutics
Start price
Target price
Perf. (%)
€33.29
03.04.17
03.04.17
€40.59
20.10.17
20.10.17
25.79%
20.10.17
20.10.17
Biolife Solutions Inc
Start price
Target price
Perf. (%)
€2.61
05.07.17
05.07.17
€2.80
14.07.17
14.07.17
27.25%
14.07.17
14.07.17
Portola Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€36.33
03.06.15
03.06.15
€40.00
07.12.15
07.12.15
23.06%
07.12.15
07.12.15
Rigel Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€1.55
01.10.14
01.10.14
€2.00
01.04.15
01.04.15
110.38%
01.04.15
01.04.15
Johnson & Johnson
Start price
Target price
Perf. (%)
€86.15
28.11.14
28.11.14
€92.00
23.01.15
23.01.15
6.79%
23.01.15
23.01.15
Could be worthwhile Investment >10% per year
Market Leader or Top 3
Known brand
Future proof or reliable business model
Johnson & Johnson
Start price
Target price
Perf. (%)
€86.15
28.11.14
28.11.14
€92.00
23.01.15
23.01.15
6.79%
23.01.15
23.01.15
Could be worthwhile Investment >10% per year
Market Leader or Top 3
Known brand
Future proof or reliable business model
Arena Pharmaceuticals Inc
Start price
Target price
Perf. (%)
€13.18
30.01.12
30.01.12
€30.00
11.05.12
11.05.12
302.12%
11.05.12
11.05.12
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€14.68
27.07.11
27.07.11
€18.00
26.01.12
26.01.12
25.99%
26.01.12
26.01.12
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€14.68
27.07.11
27.07.11
€18.00
26.01.12
26.01.12
25.99%
26.01.12
26.01.12
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€14.68
27.07.11
27.07.11
€18.00
26.01.12
26.01.12
25.99%
26.01.12
26.01.12
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued